2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-amine | 459-00-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-amine
• 英文别名: 2-methyl-1-[4-(trifluoromethyl)phenyl]propan-2-amine
• CAS: 459-00-7
• 化学式: C₁₁H₁₄F₃N
• mdl: MFCD13189646
• 分子量: 217.234
• InChiKey: LTPXSOIGSHRNFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-amine 在 盐酸 、 4-二甲氨基吡啶 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 31.17h， 生成 (S)-2-amino-N-(2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-yl)propanamide hydrochloride
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS
  [FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES ET DE TROUBLES NEURODÉGÉNÉRATIFS

  摘要：

  本公开涉及能够抑制PRMT8和/或上调SirT1的化合物。本公开还涉及治疗神经退行性疾病和障碍（例如阿尔茨海默病）的方法。

  公开号：

  WO2022076507A1
• 作为产物：
  描述：

  N-[1,1-dimethyl-2-(4-trifluoromethyl-phenyl)-ethyl]-formamide 在 盐酸 、 水 作用下， 生成 2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-amine
  参考文献：
  名称：

  Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists

  摘要：

  Novel beta(2)-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the beta(2)-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.013

文献信息

• SULFONAMIDE COMPOUNDS AND THE USE
  申请人：OGAWA Masami

  公开号：US20100022601A1

  公开（公告）日：2010-01-28

  The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like.

  提供以下式(1)的磺酰胺化合物，可用作预防或治疗包括骨质疏松症等骨疾病的CaSR拮抗剂的有效成分。这些化合物具有促进PTH分泌的卓越活性。此外，这些化合物还用作预防或治疗骨质疏松症、骨折、低甲状旁腺功能等骨疾病药物的有效成分。
• Method for producing hematopoietic stem cells using pyrazole compounds
  申请人：Nishino Taito

  公开号：US09212348B2

  公开（公告）日：2015-12-15

  An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).

  提供一种用于治疗各种造血系统疾病的造血干细胞和/或造血祖细胞的扩增剂，并用于提高基因转移效率以进行基因治疗。提供一种生产造血干细胞和/或造血祖细胞的方法，包括通过在存在以下式(I)所代表的化合物的情况下将造血干细胞在体外培养来扩增造血干细胞，该化合物的互变异构体或药用盐或其溶剂（其中R1至R8如描述中所定义）。
• PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA
  申请人：Nishino Taito

  公开号：US20130253204A1

  公开（公告）日：2013-09-26

  Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R 1 is C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with R 17 , C 1 -C 6 haloalkyl, phenyl, phenyl substituted with a R 11 's or the like, R 2 is a hydrogen atom, C 1 -C 6 alkyl, phenyl or phenyl optionally substituted with e R 21 's or the like, R 3 is a hydrogen atom or the like, X is a single bond or —(CR 6 , R 7 ) n —, each of R 4 and R 5 is independently C 1 -C 6 alkyl or the like, R 6 and R 7 are hydrogen atoms or C 1 -C 6 alkyl, R 8 is phenyl, phenyl optionally substituted with k R 81 's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

  提供了用于骨髓瘤的新型治疗药物。一种用于多发性骨髓瘤的治疗剂，包含由式（1）表示的吡唑烷化合物：其中R1是C1-C6烷基，C1-C6烷基取代为R17，C1-C6卤代烷基，苯基，苯基取代为R11或类似物，R2是氢原子，C1-C6烷基，苯基或可选地取代为e个R21或类似物，R3是氢原子或类似物，X是单键或—（CR6，R7)n—，R4和R5分别独立地是C1-C6烷基或类似物，R6和R7是氢原子或C1-C6烷基，R8是苯基，苯基可选地取代为k个R81或类似物，所述化合物的互变异构体或其药用上可接受的盐或溶剂，作为活性成分。
• Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
  申请人：Boehringer Ingelheim Pharma GmbH & Co.KG

  公开号：EP1577306A1

  公开（公告）日：2005-09-21

  Die vorliegende Erfindung betrifft die Verbindungen der allgemeinen Formel 1 worin die Reste R, R1, R2, R3 und A die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel, insbesondere zur Behandlung von entzündlichen und obstruktiven Atemwegserkrankungen.

  本发明涉及一般式1的化合物，其中残基R、R1、R2、R3和A可以具有在权利要求和说明中提及的含义，以及其制备方法和用途作为药物，特别是用于治疗炎症和阻塞性呼吸道疾病。
• Novel long acting betamimetics for the treatment of respiratory diseases
  申请人：Bouyssou Thierry

  公开号：US20050209227A1

  公开（公告）日：2005-09-22

  The present invention relates to the compounds of general formula 1 wherein the groups R, R 1 , R 2 , R 3 and A may have the meanings given in the claims and specification, processes for preparing them and their use as medicaments, particularly for the treatment of inflammatory and obstructive respiratory complaints.

  本发明涉及一般式1的化合物，其中基团R、R1、R2、R3和A可能具有在权利要求书和说明书中给出的含义，以及制备它们的过程和它们作为药物的用途，特别是用于治疗炎症和阻塞性呼吸疾病。